Cetuximab, an EGFR-targeting monoclonal antibody, is the only targeted treatment approved in the USA, Japan and Europe for HNSCC, where it is approved in combination with radiotherapy for the treatment of locoregionally advanced disease [25, 26]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.